INVARIANCE OF QUALITY OF LIFE QUESTIONNAIRE EORTC QLQC30 IN DIFFERENT CANCER INDICATIONS
Author(s)
Viada C1, Ballesteros J2, Fors M3, Luaces P1, Sanchez L1, Alvarez M1, Frias A1, Crombet T1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country, Leioa, Cuba, 3National Center of Clinical Trials, Havana, Cuba
OBJECTIVES: To validate the short version of the QLQ-C30 obtained for patients with non-small-cell lung cancer in patients with head and neck, prostate, breast or cervix cancer METHODS: We analysed data of 636 patients distributed: 237 diagnosed with head and neck cancer, 146 diagnosed with breast cancer, 140 diagnosed with cervix cancer and 113 diagnosed with prostate cancer. The analysis followed a 4-step approach. First, we conducted a Mokken nonparametric item response analysis to ascertain the QLQ-C30 dimensionality and separate several scale if appropriate. Second, we conducted a parametric Samejima’s graded response model (GRM) to assess the item characteristics and information for each scale. Third, we did a confirmatory factor analysis (CFA) to test the scales unidimensionality and to obtain standardised factor loadings to suggest a reduced version of the QLQ. Finally, we assessed the discriminative validity of the reduced version by using receiver-operator curve (ROC) analysis. RESULTS: In this study the reduction of the general questionnaire QLQ-C30 cancer 30 items to 6 scores are obtained. First it was found that 6 scores account for a 63.38% of the overall variability. Furthermore it was found that 6 score explained 62.3% of the variability in patients with head and neck cancer Nimotuzumab tratadados with a 65.53% for patients with prostate cancer treated with Nimotuzumab or CIMAvaxEGF, a 61.80% for patients with breast cancer treated with NGcGM3 and 63.83% for patients with cervical cancer treated with Nimotuzumab. 6 scores obtained correspond to the score of physical, emotional and social functional scale and the scale of symptoms of nausea and vomiting. CONCLUSIONS: The EORTC reduced scale was invariant for each indications of cancer studied; it presents good psychometric properties and includes a unidimensional structure of patient-perceived quality of life.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN130
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology